No Data
No Data
Here's Why We're Watching Barinthus Biotherapeutics' (NASDAQ:BRNS) Cash Burn Situation
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket
Barinthus Bio Cuts 25% of Staff Amid Pipeline Shakeup
H.C. Wainwright Maintains Barinthus Biotherapeutics(BRNS.US) With Buy Rating, Cuts Target Price to $5
H.C. Wainwright analyst Yi Chen maintains $Barinthus Biotherapeutics(BRNS.US)$ with a buy rating, and adjusts the target price from $8 to $5.According to TipRanks data, the analyst has a success rate
Barclays Maintains Barinthus Biotherapeutics(BRNS.US) With Buy Rating, Cuts Target Price to $3
Barclays analyst Carter Gould maintains $Barinthus Biotherapeutics(BRNS.US)$ with a buy rating, and adjusts the target price from $7 to $3.According to TipRanks data, the analyst has a success rate of
Express News | Barinthus Biotherapeutics PLC : Barclays Cuts Target Price to $3 From $7
No Data